# A Dose Escalation Study to Assess PK, Safety and Tolerability of INC280 When Taken With Food in cMET Dysregulated Advanced Solid Tumors.

> **NCT02925104** · PHASE1 · COMPLETED · sponsor: **Novartis Pharmaceuticals** · enrollment: 36 (actual)

## Conditions studied

- cMET Dysegulation Advanced Solid Tumors

## Interventions

- **DRUG:** INC280

## Key facts

- **NCT ID:** NCT02925104
- **Lead sponsor:** Novartis Pharmaceuticals
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2016-12-14
- **Primary completion:** 2018-05-16
- **Final completion:** 2018-05-16
- **Target enrollment:** 36 (ACTUAL)
- **Last updated:** 2020-12-19


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02925104

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02925104, "A Dose Escalation Study to Assess PK, Safety and Tolerability of INC280 When Taken With Food in cMET Dysregulated Advanced Solid Tumors.". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT02925104. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*